Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed advanced solid tumors who have progressed despite standard therapy, or for whom no standard therapy exists, or who might benefit from treatment with carboplatin
A minimum of 4 weeks since the last treatment with chemotherapy
WHO Performance Status 0 (able to carry out all normal activity without restriction) or 1 (restricted in physically strenuous activity but ambulatory and able to carry out work)
Age ≥ 18
Adequate hematological parameters
No major impairment of renal or hepatic function
Written informed consent obtained
You may not be if
Major surgery less than 4 weeks prior to study entry and/or not fully recovered from surgery
Chemotherapy or investigational compound less than 4 weeks prior to study entry, or planned while participating in the study
Prior administration of an epothilone
Hypersensitivity to carboplatin. Patients resistant to carboplatin are not recommended to enter the trial
Radiotherapy (RT) less than 4 weeks prior to study entry (except for palliative therapy of distant metastases), or planned RT while participating in the study
Diarrhea within 7 days prior to start of treatment. Unresolved bowel obstruction
